



Have you or your child recently been diagnosed with type 1 diabetes (T1D)?

If you or your child have recently been diagnosed with T1D, you/they may qualify to take part in the SAFEGUARD clinical study.

The SAFEGUARD study will evaluate the safety and efficacy of an investigational medicine called SAB-142 in delaying disease progression in people newly diagnosed with T1D.

Investigational means the study medicine is approved for use in clinical research but not yet approved for the general treatment of people with a certain health condition or disease.

We are looking for people who:

- ✓ Are between 5 and 40 years old
- ✓ Have recently been diagnosed with T1D

Other criteria also apply

Learn more about joining a clinical study for T1D.

What will happen during the study?

If you/your child agree to participate in the study, you will be asked to attend 2-3 screening visits where the study doctor will complete a few assessments to confirm you/your child's eligibility.

If eligible and depending on when you/your child enrolls into the study, you/they will be assigned to either Part A or Part B treatment.

For Part A, you/your child will be assigned at random (like the flip of a coin) to 1 of 2 groups to receive a high dose of SAB-142 (study medicine) or a low dose of SAB-142 (study medicine).


For Part B, you/your child will be assigned at random (like the flip of a coin) to 1 of 3 groups to receive a high dose SAB 142 (study medicine), a low dose SAB-142 (study medicine), or a placebo (a substance that looks like the study medicine but contains no active ingredients) in place of the dose.

For both parts you/your child will receive 2 treatment courses, 6 months apart. Each treatment course will be given 2 days in a row.

After each treatment course, you/your child will be required to have scheduled follow-up visits and calls to help us keep track of your/their health and monitor the safety and effectiveness of the treatment.

The total study duration for each participant will be up to 15 months from screening to the end of the study.

Additional information



There is no cost to participate in this study. All study-related clinic visits, tests, and treatment will be provided at no cost.



You/your child will continue taking prescribed T1D-related therapies for the duration of the study.



Participation is voluntary and you/your child would be able to leave the study at any point.

If you would like to learn more about the SAFEGUARD study, please contact:

.....

.....

.....

.....

.....